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treatment acceleration, as measured by weekly dose-volume/surface 
parameters. 
 
PD-0133   
Can we use a sentinel node procedure to select patients for whole-
pelvis radiotherapy in prostate cancer? 
L. Van den Bergh1, S. Joniau2, E. Lerut3, C.M. Deroose4, S. Isebaert1, 
F. Ameye2, R. Oyen5, H. Van Poppel2, K. Haustermans1 
1University Hospitals Gasthuisberg, Radiation Oncology, Leuven, 
Belgium  
2University Hospitals Gasthuisberg, Urology, Leuven, Belgium  
3University Hospitals Gasthuisberg, Pathology, Leuven, Belgium  
4University Hospitals Gasthuisberg, Nuclear Medicine, Leuven, 
Belgium  
5University Hospitals Gasthuisberg, Radiology, Leuven, Belgium  
 
Purpose/Objective: Although there are data suggesting that whole-
pelvic radiotherapy (WPRT) might improve cancer-specific survival in 
selected patients, a clear benefit has not been demonstrated yet. 
Randomized controlled trials designed to solve this question are 
urgently warranted. One of the obstacles in the treatment decision 
making process is the lack of accurate staging modalities to diagnose 
lymph node (LN) involvement so that until now, only an extended LN 
dissection ensures a full nodal staging. The objective of this study was 
to investigate the feasibility and efficacy of a sentinel node (SN) 
procedure in patients at high risk for LN involvement and to illustrate 
the impact of using this procedure in the design of a WPRT trial. 
Materials and Methods: A total of 74 patients with a risk ≥10% but 
<35% for LN metastases (Partin tables) who were node-negative (N0) 
at contrast-enhanced CT, were prospectively enrolled. Three 
transrectal 99mTc-nanocolloid injections were performed per prostate 
lobe under ultrasound guidance. Two hours later, patients underwent 
planar and SPECT imaging to facilitate localisation of the SN during 
surgery. Intraoperatively, a gamma probe was used to detect the LN 
that had taken up the radionuclide. SN were removed separately. 
After SN dissection, all patients underwent a super-extended LN 
dissection (internal, external and common iliac, obturator fossa and 
presacral regions), followed by radical prostatectomy. All retrieved LN 
were histopathologically examined. 
Results: In total, 470 SN were scintigraphically detected (patient 
median, IQR 3-9) of which 371 (patient median 4, IQR 2.25-6) were 
located and removed. In 1 patient, no SN were detected on the SPECT 
images nor intraoperatively and in 2 patients, the SN that were found 
on the SPECT images could not be retrieved during surgery.  
Histopathology confirmed LN metastases in 34 patients (46%) with a 
total of 91 affected LN (median number per patient 2, IQR 1-3) of 
which 46 LN were SN (51%). Twenty-seven of these node positive (N+) 
patients had at least 1 N+ region containing a SN, which was affected 
in 96% of the cases (26/27). However, the 6 additional N+ patients in 
whom no SN were detected in the affected region had to be taken 
into account as false negatives (FN). Therefore, sensitivity of the 
procedure decreased to 79% (26/33). If this procedure would be 
applied to select patients for a WPRT trial, no less than 21% of the N+ 
patients would not be randomized. Moreover, since SN procedure 
alone removed all affected LN in 14/33 (42%) patients, these ‘new N0’ 
patients should be taken into account for sample size calculation. 
Conclusions: Although the SN procedure was technically feasible, its 
sensitivity was too low to offer a valuable alternative to the standard 
extended LN dissection for nodal staging in these high-risk PCa. If this 
procedure would be applied to select patients for a WPRT trial, FN 
rate and the number of N0-patients due to the SN procedure should be 
taken into account.  
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Purpose/Objective: For prostate cancer patients with a large rectum 
at planning a risk of geometric miss has been suggested in recent 
literature. We also previously reported a significant decrease in tumor 
control in case of a large rectum at planning for intermediate- to 
high-risk prostate cancer patients. Now we investigated in the same 
patient group with a prolonged median follow-up of 110 months, 
whether a large rectum at planning was associated with local failure, 
regional/distant failure, and/or prostate cancer related death (PCRD), 
and to what extent this affected overall survival. 
Materials and Methods: Patients from a multicenter trial (randomized 
between 78 Gy and 68 Gy) with data on acute diarrhea and with an 
estimated seminal vesicle involvement of >25 % were included 
(n=349). Planning target volume was the prostate and seminal vesicles 
with a margin of 1 cm for the first 68 Gy and a margin of 5 mm for the 
10 Gy boost when applicable with 0 mm margin towards the rectum. 
Investigated risk factors for geometric miss were (similar to our 
previous study): rectal volume ≥90 cm3 and diarrhea reported during 
at least 25% of treatment (RF1, n=87/349), and cross-sectional area 
(CSA) of the rectum >8 cm (RF2, n=83/349) regardless reported 
diarrhea. CSA was calculated by dividing the rectal volume by the 
rectal length in cranial-caudal direction. We calculated Hazard Ratios 
(HR) and Kaplan Meier curves for each outcome, stratifying for the 
dose arms. 
Results: There were 68 cases of PRCD, 26 cases of local failure as first 
event, and 73 cases of regional/distant failure as first event. 
Surprisingly, there was no increased risk for local failure (Figure) for 
both risk factors (HRs≈1) while they were associated with a higher risk 
of regional/distant failure (Figure): HR=1.6 (p=0.06) for RF1 and 
HR=2.0 for RF2 (p=0.007), and with increased rates of PCRD: HR=1.9 
(p=0.01) and HR=1.7 (p=0.04), respectively. The estimated difference 
in disease specific survival was 14% at 10 years (Figure) for RF1 (68 % 
versus 82 %). The corresponding overall survival curve showed a 
difference of only 6 % at 10 years (60 % versus 66 %).  
 
  
Conclusions: Patients with a large rectum at planning had no 
increased risk for local failure, which considerably weakens the 
hypothesis of 'geometric miss'. Apparently the local tumor was not 
missed during treatment. An alternative hypothesis for the observed 
increase in regional/distant failure could be that a large rectum at 
planning is associated with geometrical miss outside the prostate, i.e. 
extraprostatic disease in -for instance- lymph node areas receiving 
less (unintended) dose due to a ventral shift of the dose distributions.  
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Purpose/Objective: Several reports have suggested an impact of 
treatment parameters such as radiation dose, treatment margin and 
image guidance (IG) of radiotherapy (RT) delivery on Prostate Cancer 
(PCa) treatment outcomes. The purpose of this work is to review 
published actuarial estimates of Prostate Specific Antigen Relapse 
Free Survival (PRFS) for high-risk disease treated by 3DCRT, IMRT or 
IG-IMRT with or without Androgen Depravation Therapy (ADT), and 
establish the dose-response relationship.  
Materials and Methods: PubMed searches were performed on PCa 
outcomes following external beam RT. Data on treatment margin, use 
and duration of ADT, prescribed radiation dose, treatment 
technique(IMRT/IGRT), randomized trial, PRFS (Phoenix definition) at 
3, 4, 5 and 7-years for high risk PCa were collected. Dose per fraction 
was corrected to 2 Gy-equivalent doses using an α/β of 1.4. In order 
to limit the uncertainty of the procedure, only trials with moderate 
fractionation were included (3.1Gy/fr. or less). A funnel plot was used 
to investigate publication bias. A multivariate analysis of the 
parameters were performed to clarify if data from all studies could be 
pooled (p-values <0.05 were considered significant). A logistic 
regression curve was fitted to the PRFS and dose data at each time 
point. The gradient (γ50) and the dose required to obtain 50% PRFS 
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(D50) were fitting parameters and studies were weighted using inverse 
variance (see Eq. 1).  
PRFS=1/(1+exp(4·γ50·(1-D/D50))) [Eq.1] 
Results: A total of ca 4000 publications were reviewed of which 15 
met the acceptance criteria, providing a total of 28 dose level 
outcome data at 1-4 time points. A total of 6/28 were using IG-IMRT, 
7/28 IMRT, 15/28 3DCRT and 6/28 were randomized trials. IG, IMRT 
and radiation dose were associated with improved PRFS at 5 years 
(Table 1), while randomized trials (yes/no), the frequency of use or 
duration of ADT were not.Only the radiation dose remained significant 
in a multivariate analysis, indicating that a pooled analysis of all 
studies was reasonable. The gradient of the dose response curve (γ50) 
was ca 1.5% at 3-7 years, and the dose required to obtain 50% PRFS 
(D50) was significantly different at 3 vs. 5 and 7 years (p<0.001) (Fig. 
1.). A reduction of 6% in PRFS per year was estimated for year 3-5 
post RT. Increased treatment margin tended to improve PRFS 
independent of IGRT use. No publication bias was evident.  
 
 
 
Conclusions: High-dose IG-IMRT was associated with superior PRFS vs. 
low-dose RT for high-risk PCa. PRFS at 3 years can potentially be used 
to predict outcome at 4-7 years. The possibility of a minor effect on 
PRFS by reducing the treatment margin could be discerned. By 
extrapolation of our model, RT to ca 85-95 Gy in equivalent dose in 2-
Gy fractions is predicted to improve PRFS for high-risk PCa, after 
which the local control plateaus and the benefit diminishes.  
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Purpose/Objective: The dose-response relationship for prostate 
radiotherapy has been demonstrated in several clinical trials with an 
advantage for high dose treatments. Established prognostic factors; 
including tumour stage, Gleason score, and PSA explain only a 
moderate proportion of the variation in outcome following prostate 
radiotherapy. There are no reliable predictors to determine which 
patients are likely to benefit from the extra dose. Prostate cancer 
exhibits regions of hypoxia with oxygen partial pressures that are 
likely to have radiobiological significance. The concept of the oxygen 
enhancement ratio is well established and it is possible that hypoxia 
biomarkers may predict which patients require dose escalation. We 
aimed to study the predictive value of intrinsic biomarkers of tumour 
hypoxia (GLUT1, HIF1α and osteopontin (OPN)) in patients treated 
with radiotherapy for localised prostate cancer. 
Materials and Methods: Paraffin embedded prostate biopsies were 
collected from patients enrolled into a trial of external beam 
radiotherapy (EBRT) versus combined EBRT followed by a high dose 
rate (HDR) brachytherapy boost.  
Immunohistochemical staining was performed for GLUT1, HIF1αand 
OPN using monoclonal antibodies. Tumours were assessed for 
biomarker expression by two independent investigators, blinded to 
patient outcome and scored as negative or positive depending upon 
the proportion of cells staining for the marker in question. 
Biochemical relapse free interval for all patients was determined 
using the Kaplan-Meier method. 
Results: 191 samples were included in the analysis. Hif1α, Glut1 and 
OPN expression were all significantly associated with a shorter 
biochemical relapse free interval (see figure and table). High dose 
radiotherapy (EBRT plus HDR boost) was advantageous over 
conventional dose radiotherapy (EBRT alone) for patients that 
exhibited OPN expression (p=0.017) but not for patients with negative 
OPN staining (p=0.349). Conversely, for GLUT1, high dose 
radiotherapy was only advantageous over conventional dose 
radiotherapy for patients that lacked GLUT1 expression (p=0.006).  
 
 
  
Conclusions: Overall, expression of OPN, HIF1α or GLUT1 confers a 
poorer prognosis for patients receiving prostate radiotherapy 
compared to those that do not express these hypoxia biomarkers. 
Furthermore, these data generate the following hypothesis: OPN 
becomes positive in the presence of mild/moderate hypoxia, GLUT1 
only becomes positive under conditions of severe hypoxia. Therefore, 
If both OPN and GLUT1 are negative (i.e. minimal hypoxia), there is 
no benefit from dose escalation. If OPN is positive and GLUT1 is 
negative (moderate hypoxia), there is a benefit for dose escalation. 
However, If GLUT1 is positive (severe hypoxia), there is no benefit 
from dose escalation because patients will do badly despite very high 
doses of radiotherapy. Further evaluation using an independent data 
set is ongoing.  
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Purpose/Objective: Daily location of the target volume has become a 
usual clinical practice after introduction of portal imaging devices. 
The actual information on the day of treatment is used to relocate the 
patient to maximize target coverage. However, relocation is not 
capable to account for large deformations of structures of interest, 
and the therapeutic ratio remains lower then desired. We propose a 
method of generating triple-arc IMAT plans to treat prostate cancer 
